Fenfluramine-induced increase in preproenkephalin mRNA levels in the striatum: Interaction between the serotonergic, glutamatergic, and dopaminergic systems

Synapse

Volumn 35, Issue 3, 2000, Pages 182-191

  Liste, Isabel ^a   Muñoz, Ana ^a   Guerra, Maria Jose ^a   Labandeira Garcia, Jose Luis ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Basal ganglia; Dopamine; Enkephalin; Fenfluramine; Glutamate; Serotonin

Indexed keywords

5,7 DIHYDROXYTRYPTAMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DIZOCILPINE; FENCLONINE; FENFLURAMINE; MESSENGER RNA; OXIDOPAMINE; PREPROENKEPHALIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEAFFERENTATION; FEMALE; IN SITU HYBRIDIZATION; NONHUMAN; PRIORITY JOURNAL; RAT;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 5,7-DIHYDROXYTRYPTAMINE; ADRENERGIC AGENTS; ANIMALS; CORPUS STRIATUM; DIZOCILPINE MALEATE; ENKEPHALINS; FEMALE; FENFLURAMINE; OXIDOPAMINE; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SEROTONIN AGENTS;

EID: 0342905393     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(20000301)35:3<182::AID-SYN3>3.0.CO;2-T     Document Type: Article

References (75)

1. Albin RL, Young AB, Penney JB. 1989. The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375.
2. Balcioglu A, Wurtman RJ. 1998. Dexfenfluramine enhances striatal dopamine release in conscious rats via a serotonergic mechanism. J Pharmacol Exp Ther 284:991-997.
3. Bath RV, Baraban JM. 1993. Activation of transcription factor genes in striatum by cocaine: role of both serotonin and dopamine systems. J Pharmacol Exp Ther 267:496-505.
4. Beart PM, McDonald D. 1982. 5-Hydroxytriptamine and 5-hydroxytriptaminergic-dopaminergic interactions in the ventral tegmental area of the rat brain. J Pharm Pharmacol 34:591-593.
5. Bischoff S, Heinrich M, Sonntag JM, Kraus K. 1986. The D1 dopamine receptor antagonist SCH-23390 also interact with brain serotonin (5-HT2) receptors. Eur J Pharmacol 129:367-370.
6. Bonhomme N, De Deruwaerdre P, Le Moal M, Spampinato U. 1995. Evidence for 5-HT4 receptor subtype involvement in the enhancement of dopamine release induced by serotonin: a microdialisis study in the halothane-anesthetized rats. Neuropharmacology 34: 269-279.
7. Caillé I, Dumartin B, Bloch B. 1996. Ultrastructural localization of D1 dopamine receptor immunoreactivity in the rat striatonigral neurons and its relation with dopaminergic innervation. Brain Res 730:17-31.
8. Cameron DL, Williams JT. 1993. Dopamine D1 receptors facilitate transmiter release. Nature 366:344-347.
9. Campbell K, Björklund A. 1994. Prefrontal corticostriatal afferents maintain increased enkephalin gene expression in the dopamine-denervated rat striatum. Eur J Neurosci 6:1371-1383.
10. Cenci MA, Campbell K, Björklund A. 1993. Neuropeptide messenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphin messenger RNA levels. Neuroscience 4:275-296.
11. Cepeda C, Buchwald NA, Levine MS. 1993. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci USA 90:9576-9580.
12. Chesselet MF, Delfs JM. 1996. Basal ganglia and movement disorders: an update. Trends Neurosci 19:417-422.
13. Compan V, Salin P, Daszuta A. 1997. Selective effects of partial and severe lesions of the serotoninergic systems on Met-enkephalin and substance P neurons in rat basal ganglia. Mol Brain Res 50:246-256.
14. Cook DF, Wirshafter D. 1995. Serotonin agonist-induced c-fos expression in the rat striatum. Soc Neurosci Abstr 21:1424.
15. De Deurwaerdére P, Bonhomme N, Le Moal M, Spampinato U. 1995. d-Fenfluramine increases striatal dopamine in vivo independently of serotonergic terminals or dopamine uptake sites. J Neurochem 65:1100-1108.
16. De Deurwaerdére P, Bonhomme N, Lucas G, Le Moal M, Spampinato U. 1996. Serotonin enhances dopamine outflow in vivo through dopamine uptake sites. J Neurochem 66:210-215.
17. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JMA. 1989. A "glutamatergic hypothesis" of schizophrenia. Clin Neuropharmacol 12:1-13.
18. Deward KM, Grondin L, Carli M, Lima L, Reader TA. 1992. 3[H] Paroxine binding and serotonin content of rat cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and mid-brain raphe following p-chlorophenylalanine and p-chloroamphetamine treatment. J Neurochem 58:250-257.
19. Eriksson E, Humble M. 1990. Serotonin in psychiatric pathophysiology. In: Pohl R, Gershon S, editors. The biological basis of psychiatric treatment. Prog Basic Clin Pharmacol, vol 3. Farmington CT: S. Karger, p 66-119.
20. Gerfen CR. 1992. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 15:133-138.
21. Gerfen CR, McGinty JF, Young WS III. 1991. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J Neurosci 11:1016-1031.
22. Gerfen CR, Keefe KA, Gauda EB. 1995. D1 and D2 dopamine receptor function in the striatum: coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons. J Neurosci 15:9167-8176.
23. Guerra MJ, Liste I, Labandeira-Garcia JL. 1997. Effects of lesions of the nigrostriatal pathway and of nigral grafts on striatal serotonergic innervation in adult rats. NeuroReport 8:3485-3488.
24. Guerra MJ, Liste I, Labandeira-Garcia JL. 1998. Interaction between the serotonergic, dopaminergic, and glutamatergic systems in fenfluramine-induced Fos expression in striatal neurons. Synapse 28: 71-82.
25. Haber SN, Lu W. 1995. Distribution of preproenkephalin messenger RNA in the basal ganglia and limbic-associated region of the monkey telencephalon. Neuroscience 65:417-429.
26. Hajji MD, Salin P, Kerkian-Le Goff L. 1996. Chronic dizocilpine maleate (MK-801) treatment suppresses the effects of nigrostriatal dopamine deafferentation on enkephalin but not on substance P expression in the rat striatum. Eur J Neurosci 8:917-926.
27. Hammer RP Jr, Bogic L, Handa RJ. 1993. Estrogenic regulation of proenkephalin mRNA expression in the ventromedial hypothalamus of the adult male rat. Mol Brain Res 19:129-134.
28. Hanson GR, Singh N, Bush L, Gib JW. 1991. Response of extrapyramidal and limbic neuropeptides to fenfluramine administration: comparison with methamphetamine. J Pharmacol Exp Ther 259:1197-1202.
29. Howells RD, Kilpatrick DL, Bhatt R, Monahan JJ, Poonian M, Udenfriend S. 1984. Molecular cloning and sequence determination of rat preproenkephalin cDNA: sensitive probe for studying transcriptional changes in rat tissues. Proc Natl Acad Sci USA 81:7651-7655.
30. Hudson JL, Van Horne CG, Stromberg I, Brock S, Clayton J, Masserano J, Hoffer BJ, Gerhardt GA. 1993. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 626:167-174.
31. Hurd YL, Herkehnham M. 1992. Influence of a single injection of cocaine, amphetamine or GBR 12909 on mRNA expression of striatal neuropeptides. Mol Brain Res 13:97-104.
32. Hurd YL, Brown EE, Finlay JM, Fibiger HC, Gerfen CR. 1992. Cocaine self-administration differentially alters mRNA expression of striatal peptides. Mol Brain Res 13:165-170.
33. Jaber M, Cador M, Dumartin B, Normand E, Stinus L, Bloch B. 1995. Acute and chronic amphetamine treatments differently regulate neuropeptide messenger RNA levels and Fos immunoreactivity in rat striatal neurons. Neuroscience 65:1041-1050.
34. Jaeger D, Kita H, Wilson CJ. 1994. Surround inhibition among projection neurons is weak or nonexistent in the rat neostriatum. J Neurophysiol 72:2555-2558.
35. Johnson SW, Mercuri NB, North RA. 1992. 5-Hydroxytriptamine 1B receptors block the GABA B synaptic potential in rat dopamine neurons. J Neurosci 12:2000-2006.
36. Jolkkonen J, Jenner P, Marsden CD. 1994. Gabaergic modulation of striatal peptide expression in rats and the alterations induced by dopamine antagonist treatment. Neurosci Lett 180:273-276.
37. Kalivas PW. 1993. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Rev 18:75-113.
38. Karstaedt PJ, Kerasidis H, Pincus JH, Meloni R, Graham J, Gale K. 1994. Unilateral destruction of dopamine pathways increases ipsilateral striatal serotonin turnover in rats. Exp Neurol 126:25-30.
39. Keefe KA, Gerfen CR. 1995. D1-D2 dopamine receptor synergy in striatum: effects of intrastriatal infusions of dopamine agonist and antagonist on immediate early gene expression. Neuroscience 66: 903-913.
40. Koe BK, Weissman A. 1966. p-Chlorophenylalanine: a specific depletor of brain serotonin. J Pharmacol Exp Ther 154:499-516.
41. Kozlowsky MR, Marshall JF. 1980. Plasticity of [14C]2-deoxy-D-glucose incorporation into neostriatum and related structures in response to dopamine neuron damage and apomorphine replacement. Brain Res 197:167-183.
42. Labandeira-Garcia JL, Rozas G, Lopez-Martin E, Liste I, Guerra MJ. 1996. Time course of striatal changes induced by 6-hydroxydopamine lesion of the nigrostriatal pathway, as studied by combined evaluation of rotational behaviour and striatal Fos expression. Exp Brain Res 108:69-84.
43. Le Moine C, Svenningsson P, Fredholm BE, Bloch B. 1997. Dopamine-adenosine interactions in the striatum and in the globus pallidus: inhibition of striatopallidal neurons through either D2 or A2A receptors enhances D1 receptor-mediated effects on c-fos expression. J Neurosci 15:8038-8048.
44. Li Y, McGivern RF, Nagahara AH, Handa RJ. 1997. Alterations in the estrogen sensitivity of hypothalamic proenkephalin mRNA expression with age and prenatal exposure to alcohol. Mol Brain Res 47:215-222.
45. Liste I, Rozas G, Guerra MJ, Labandeira-Garcia JL. 1995. Cortical stimulation induces Fos expression in striatal neurons via NMDA glutamate and dopamine receptors. Brain Res 700:1-12.
46. Mocchetti I, Giorgi O, Schwartz JP, Costa E. 1985a. A reduction of the tone of 5-hydroxitryptamine neurons decreases utilization rates of striatal and hypothalamic enkephalins. Eur J Pharmacol 106:427-430.
47. Mocchetti I, Schwartz JP, Costa E. 1985b. Use of mRNA hybridization and radioimmunoassay to study mechanism of drug-induced accumulation of enkephalins in rat brain structures. Mol Pharmacol 28:86-91.
48. Morris BJ, Hunt SP. 1991. Proenkephalin mRNA levels in rat striatum are increased and decreased, respectively, by selective D2 and D1 dopamine receptor antagonist. Neurosci Lett 125:201-204.
49. Morris BJ, Reimer S, Höllt V, Herz A. 1988a. Regulation of striatal prodynorphin mRNA levels by the raphe-striatal pathway. Mol Brain Res 4:15-22.
50. Morris BJ, Höllt V, Herz A. 1988b. Dopaminergic regulation of striatal proenkephalin mRNA and prodynorphin mRNA: contrasting effects of D1 and D2 antagonist. Neuroscience 25:525-532.
51. Noailles P-A H, Villegas M, Ledoux M, Lucas LR, McEwen BS, Angulo JA. 1996. Acute treatment with the N-methyl-D-aspartate receptor antagonist MK-801: effect of concurrent administration of haloperidol or scopolamine on preproenkephalin mRNA levels of the striatum and nucleus accumbens of the rat brain. Neurosci Lett 202:165-168.
52. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates. New York: Academic Press.
53. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. 1975. Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 10:241-323.
54. Pirot S, Godbout R, Mantz J, Tassin J-P, Glowinski J, Thierry AM. 1992. Inhibitory effects of ventral tegmental area stimulation on the activity of prefrontal cortical neurons: evidence for the involvement of both dopaminergic and GABAergic components. Neuroscience 49:857-865.
55. Rea WP, Rothman RB, Shippenberg TS. 1998. Evaluation of the conditioned reinforcing effects of phentermine and fenfluramine in the rat: concordance with clinical studies. Synapse 30:107-111.
56. Reiner A, Anderson KD. 1990. The patterns of neurotransmitter and neuropeptide co-occurrence among striatal projections neurons: conclusions based on recent findings. Brain Res Rev 15:251-256.
57. Rowland NE, Carlton J. 1986. Neurobiology of an anorectic drug: fenfluramine. Prog Neurol 27:13-62.
58. Rozas G, Liste I, Guerra MJ, Labandeira-Garcia JL. 1998. Sprouting of serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett 245:151-154.
59. Schmidt RH, Björklund A, Stenevi U, Dunnett SB, Gage FH. 1983. Intracerebral grafting of neuronal cell suspensions. III. Activity of intrastriatal nigral suspension implants as assessed by measurement of dopamine synthesis and metabolism. Acta Physiol Scand 522:19-28.
60. Smith AJW, McGinty JF. 1994. Acute amphetamine or methamphetamine alters opioid peptide mRNA expression in rat striatum. Mol Brain Res 21:359-362.
61. Somers DL, Beckstead RM. 1992. N-methyl-D-aspartate receptor antagonism alters substance P and Met5-enkephalin biosynthesis in neurons of the rat striatum. Pharmacol Exp Ther 262:823-833.
62. Surmeier DJ, Reiner A, Levine MS, Ariano MA. 1993. Are neostriatal dopamine receptors co-localized? Trends Neurosci 16:299-305.
63. Torres G. 1995. Fenfluramine-induced c-fos in the striatum and hypothalamus: a tract-tracing study. Neuroreport 6:1679-1683.
64. Torres G, Rivier C. 1994. Induction of c-fos in rat brain by acute cocaine and fenfluramine exposure: a comparison study. Brain Res 647:1-9.
65. Vincent SL, Khan Y, Benes FM. 1993. Cellular distribution of dopamine D1 and D2 receptors in rat medial prefrontal cortex. J Neurosci 13:2551-2564.
66. Voorn P, Roest G, Groenewegen HJ. 1987. Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions. Brain Res 412:391-396.
67. Walker PD, Capodilupo JG, Wolf WA, Carlock LR. 1996. Preprotachykinin and preproenkephalin mRNA expression within striatal subregions in response to altered serotonin transmission. Brain Res 732:25-35.
68. Wang JQ, McGinty JF. 1996a. Acute methamphetamine-induced zif/268, preprodynorphin, and preproenkephalin mRNA expression in rat striatum depends on activation of NMDA and kainate/AMPA receptors. Brain Res Bull 39:349-357.
69. Wang JQ, McGinty JF. 1996b. D1 and D2 receptor regulation of preproenkephalin and preprodynorphin mRNA in rat striatum following acute injection of amphetamine or methamphetamine. Synapse 22:114-122.
70. Wang JQ, McGinty JF. 1997. The full D1 dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D1/D2 interactions by muscarinic receptors. J Pharmacol Exp Ther 281:972-982.
71. Wang JQ, Daunais JB, McGinty JF. 1994. NMDA receptors mediate amphetamine-induced upregulation of zif/268 and preprodynorphin mRNA expression in rat striatum. Synapse 18:343-353.
72. Williams J, Davies JA. 1983. The involvement of 5-hydroxytriptamine in the release of dendritic dopamine from slices of rat substantia nigra. J Pharm Pharmacol 35:734-737.
73. Wooten GF, Collins RC. 1983. Effects of dopaminergic stimulation on functional brain metabolism in rats with unilateral substantia nigra lesion. Brain Res 263:267-275.
74. Yung KK, Smith AD, Levey AI, Bolam JP. 1996. Synaptic connections between spiny neurons of the direct and indirect pathways in the neostriatum of the rat: evidence from dopamine receptor and neuropeptides immunostaining. Eur J Neurosci 8:861-869.
75. Zaczek R, Battaglia G, Culp S, Appel J, Contrera N, DeSouza E. 1990. Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: pharmacokinetic, dose response, regional specificity and time course data. J Pharmacol Exp Ther 252:104-112.